Tocilizumab - Covid-19

You are here : Home > Formulary Search > Tocilizumab - Covid-19

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Not Specified

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

NICE

Restrictions / Comments :

Documentation

Evidence Review

NICE TA878 CMDU APC briefing paper Jun-23.doc

Webpage

NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

Information

CMDU Community Pharmacies June 2025.pdf

PAD Profile

ChemicalSubstance :

Tocilizumab

Indication :

Covid-19

Group Name :

Keywords :

CMDU, covid medicines delivery unit, monoclonal antibody, MAB,

Brand Names Include :

RoActemRA, Tyenne

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Tocilizumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Covid-19.

Committee Recommendations (1)

05 Jul 23 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartland Integrated Care System Area Prescribing Committee agree implementation of NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19.

Tocilizumab is agreed as RED only for administration in the hospital setting